ANXA1 and the risk for early-onset Parkinson's disease

Article Geriatrics & Gerontology

Mutation analysis of seven SLC family transporters for early-onset Parkinson's disease in Chinese population

ChunYu Li et al.

Summary: This study systematically analyzed the genetic involvement of solute carrier (SLC) transporters in early-onset Parkinson's disease (EOPD) by investigating rare variants in 743 Chinese EOPD patients. The study identified SLC2A13 as a risk gene for PD, and expanded the current mutation spectrum of PD.

NEUROBIOLOGY OF AGING (2021)

Add to Collection

Article Clinical Neurology

ANXA1 with Anti-Inflammatory Properties Might Contribute to Parkinsonism

Hossein Darvish et al.

Summary: This study identified a novel variant in the anti-inflammatory protein Annexin A1, which likely causes autosomal recessive parkinsonism in two siblings. The variant affects phagocytosis in zebrafish mutant embryos and impacts a functional domain of the protein, supporting the hypothesis that damaged microglia could lead to parkinsonism.

ANNALS OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Annexin A1 restores cerebrovascular integrity concomitant with reduced amyloid-β and tau pathology

Miriam Ries et al.

Summary: Treatment with hrANXA1 has shown beneficial effects in Alzheimer's disease, restoring blood-brain barrier function, decreasing amyloid-beta and tau pathology, rescuing vascular defects, and reducing brain amyloid-beta load. Additionally, hrANXA1 exhibits systemic anti-inflammatory properties and can improve memory deficits and synaptic density. The data suggest hrANXA1 as a potential therapeutic approach for Alzheimer's disease.

BRAIN (2021)

Add to Collection

Review Clinical Neurology